• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • China Clinical Trials GCP – Important Changes for the Administration of Medical Device & IVD Clinical Trials

China Clinical Trials GCP – Important Changes for the Administration of Medical Device & IVD Clinical Trials

China clinical trials gcp
Monday, 25 April 2022 / Published in Medical Device, News, NMPA Registration in China

China Clinical Trials GCP – Important Changes for the Administration of Medical Device & IVD Clinical Trials

The China Clinical Trials GCP (Good Clinical Practice) 2022 amended version will come into effect on May 1, 2022.

Running, or planning, clinical trials in China for medical device or IVD?

In March 2022, the National Medical Products Administration (NMPA) and National Health Commission (NHC) have released important updated clinical practice requirements for clinical trials in China for medical device and IVD:

  • Good Clinical Practice for Medical Devices (Decree No.28)
  • Matters related to the implementation of the good management practice for clinical trials of medical devices (No.21-2022)

China Clinical Trials GCP – Key Changes

Manufacturers, sponsors and others running or planning clinical trials should be aware about the following key changes to the regulation framework for their China clinical trials:

  • The adjustment structure has been clarified and emphasizes the responsibilities of all parties:
    • Highlight the main responsibility of the sponsor, introduce the concept of risk management, and clearly stipulate that the quality management system of the sponsor should cover the whole process of clinical trials of medical devices;
    • Strengthen the requirements of clinical trial institutions for medical devices, clinical trial institutions should establish a clinical trial management organizational structure and management system;
    • Emphasize the responsibilities of researchers, and researchers should implement clinical trials of medical devices in accordance with the provisions of the Code and relevant laws and regulations.
  • Key documentation guidance for clinical trial reports, adverse event reports and basic documentation have been updated and clarified.
  • In order to facilitate smooth implementation of clinical trials, the 1-year validity of test reports no longer exists.
  • Reporting safety information to the respective MPA and health management departments no longer need to be submitted as a “dual report” by the sponsor and investigator, but instead, a “single report” by the sponsor will suffice.

Manufacturers, sponsors, CROs and others involved in clinical trials in China should study the new guideline closely.

By Hamish King and Jacky Li. Cisema regularly support clinical trials in China as a CRO. For our clinical trial protocol and preparatory studies, or more details about full support in accordance with the China clinical trials GCP, please inform us.

Tagged under: Clinical Trials, GCP, Good Clinical Practice, medical device

What you can read next

cosmetics adverse reactions collection and reporting
Cosmetics adverse reactions collection and reporting guidelines for registrants and filers (Trial) – Draft issued
Quality Control on Coronary Stents Increased Following China’s Recent Centralized Procurement Program
NMPA Strengthens Supervision of Medical Devices for China Procurement

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • China medical device sampling inspection results

    China medical device sampling inspection results no.4 of 2022

    China medical device sampling inspection result...
  • NMPA cosmetic sampling inspection

    The NMPA Cosmetic Sampling Inspection measures come into force on March 1, 2023

    NMPA Cosmetic Sampling Inspection Measures come...
  • China cosmetics quality safety responsibilities

    China cosmetics quality and safety responsibilities regulations released

    China cosmetics quality and safety responsibili...
  • China cosmetics efficacy claims FAQ

    China cosmetics efficacy claims FAQ available to answer key questions

    China cosmetics efficacy claims FAQ is availabl...
  • China cosmetics GMP inspections

    China cosmetics GMP inspections points have been finalised

    China cosmetics GMP inspections points and judg...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.